HomeCompanies › BCTX

BriaCell Therapeutics

Most recent annual filing: 2025-10-16

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Bria-IMT + CPI Ph3 interim2026Bria-IMT + CPI Ph3 interim, 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

TILsRx

Proprietary platform designed to activate tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment; integrates T cell engagers and immune checkpoint modulators; multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets; focus areas include prostate, lung, breast, pancreatic, and ovarian cancers; early agents include antibodies to B7-H3

Targets: B7-H3

Bria-TILsRx

Quadrivalent multi-specific binding reagents designed as potent immune cell activators and/or immune checkpoint inhibitors; selectively target and destroy cancer cells while minimizing effects on normal cells; focus on immuno-oncology across multiple cancer types

Targets: B7-H3

Bria-OTS+

Off-the-shelf cellular immunotherapy platform using premanufactured, HLA-matched, genetically modified whole-cell cancer vaccine lines designed to activate innate and adaptive immunity; basis for Bria-MEL+ (melanoma), Bria-PROS+ (prostate cancer), and Bria-OTS (breast cancer) programs.

Biotech Distilled coverage (6)

Articles open on Substack. Some deep dives are subscriber-only.